NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
Ramy Ashry1,2, Al-Hassan M Mustafa1,3, Kristin Hausmann4
1Institute of Toxicology, University Medical Centre Mainz, 55131 Mainz, Germany.
Abstract:
Epigenetic modifiers of the histone deacetylase (HDAC) family are often dysregulated in cancer cells. Experiments with small molecule HDAC inhibitors (HDACi) have proven that HDACs are a vulnerability of transformed cells. We evaluated a novel hydroxamic acid-based HDACi (KH16; termed yanostat) in human pancreatic ductal adenocarcinoma (PDAC) cells, short- and long-term cultured colorectal cancer (CRC) cells, and retinal pigment epithelial cells. We show that KH16 induces cell cycle arrest and apoptosis, both time and dose dependently in PDAC and CRC cells. This is associated with altered expression of BCL2 family members controlling intrinsic apoptosis. Recent data illustrate that PDAC cells frequently have an altered expression of the pro-apoptotic BH3-only protein NOXA and that HDACi induce an accumulation of NOXA. Using PDAC cells with a deletion of NOXA by CRISPR-Cas9, we found that a lack of NOXA delayed apoptosis induction by KH16. These results suggest that KH16 is a new chemotype of hydroxamic acid HDACi with superior activity against solid tumor-derived cells. Thus, KH16 is a scaffold for future research on compounds with nanomolar activity against HDACs.
Insights
A novel hydroxamic acid-based histone deacetylase inhibitor (HDACi), KH16, effectively induces apoptosis in pancreatic and colorectal cancer cells. Its efficacy is partly mediated by the NOXA protein, suggesting KH16 as a promising scaffold for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Histone deacetylases (HDACs) are frequently dysregulated in cancer.
- Small molecule HDAC inhibitors (HDACi) demonstrate cancer cell vulnerability.
- Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are significant health concerns.
Purpose of the Study:
- To evaluate a novel hydroxamic acid-based HDACi, KH16 (yanostat), in cancer cells.
- To investigate the mechanism of KH16-induced apoptosis.
- To assess the role of the NOXA protein in KH16's anti-cancer effects.
Main Methods:
- Treatment of PDAC, CRC, and retinal pigment epithelial cells with KH16.
- Assessment of cell cycle arrest and apoptosis.
- Analysis of BCL2 family member expression.
- CRISPR-Cas9 mediated NOXA deletion in PDAC cells.
Main Results:
- KH16 induced time- and dose-dependent cell cycle arrest and apoptosis in PDAC and CRC cells.
- Apoptosis induction was linked to altered BCL2 family member expression.
- KH16 treatment led to NOXA accumulation.
- Absence of NOXA delayed KH16-induced apoptosis.
Conclusions:
- KH16 is a potent hydroxamic acid-based HDACi with superior activity against solid tumor cells.
- NOXA plays a role in KH16-mediated apoptosis.
- KH16 serves as a scaffold for developing novel HDAC inhibitors with nanomolar activity.
Related Concept Videos
Apoptosis
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Caspases


